Unichem Laboratories Ltd

- No explicit mention of any new fundraising through equity in the transcript. - An increase in consolidated long-term borrowings was noted, primarily due to subsidiaries' working capital requirements, with tenures slightly over one year. - Debt cost details were not fully disclosed; cost of debt was discussed but without specific new debt announcements. - Capex guidance for FY2017 and FY2018 was Rs. 150 to 200 Crores, primarily funded internally for new API facilities and expansions. - No direct statements about plans for raising fresh equity or debt beyond existing borrowings and capex plans.

- Capex guidance for FY2017 and FY2018 is around Rs. 150 to 200 Crores, some of which may spill over to FY2018. - Major capital expenditure is focused on the new API facility near Kolhapur, Maharashtra. - Significant past capex incurred on the Goa plant, which is expected to be commissioned soon. - Biosciences pilot plant also accounted for part of recent capital expenditure. - Other expenditures mainly relate to maintenance and debottlenecking at existing plants. - The Kolhapur API plant is still a few quarters away from starting operations and will require US FDA approval. - Company plans to realign products between US FDA approved plants and the new facility to sustain US growth. - No aggressive increase planned in contract manufacturing business until new capacities come online.

- US business expected to maintain robust growth with over 30% increase, supported by 16 pending approvals and new product launches. - Domestic business aims for double-digit growth despite challenges from pricing regulations, focusing on volume increase and new product introductions across verticals. - Domestic growth driven by improved per man productivity (above Rs. 2 lakhs) and expansion in cardiovascular and acute therapy clusters. - Niche generics targeting breakeven soon with product launches in both US and tender markets to enhance traction and profitability. - API plant at Kolhapur and biosciences pilot plant expansions expected to support future capacity and supply needs. - Increased ANDA filings planned—aiming for 6 to 8 filings annually to sustain product pipeline growth in regulated markets. - Overall, growth expected from a better product mix, expanding sales, and leveraging regulatory approvals in key international markets.

- The company expects continued double-digit growth in topline driven by the US business and domestic formulation segments. - US subsidiary experienced over 30% growth and targets maintaining this momentum with 6-8 ANDA filings this year. - Domestic business aims to sustain high single-digit to low double-digit growth through volume increases and new products, despite challenges in pricing and market dynamics. - Operating margins are expected to improve by 100 to 150 basis points driven by a better product mix and sales growth, although operating costs might not reduce significantly. - Niche generics segment is close to breakeven and expected to turn profitable with capacity expansion and new product launches. - Consolidated breakeven after R&D expense is targeted from next year onwards, compared to partial R&D recovery currently. - Capital expenditure planned at Rs. 150-200 Crores mainly towards new API capacities, which will support future growth. - R&D spend remains steady at 4-5% of turnover, with potential increase if opportunities arise.

- The company has around 16 pending approvals in the US market. - They have plans to file 2-3 ANDAs in Q1 FY17 and aim to maintain a filing rate of 1-2 filings every quarter, targeting 6-8 filings annually. - Currently, 20 ANDAs are approved, with 14 products already launched, 2 expected launches in Q1, and a few more planned for Q2. - The US subsidiary shows strong growth with focus on launching niche/high-value products and Para IV opportunities. - New capacities, including a plant near Kolhapur and expansion at Goa, are expected to support upcoming filings and commercial launches. - The growth strategy is linked to the product approvals pipeline and capacity expansions, aiming to maintain and increase US business growth.